The high-dose FVIII regimen was used in a 3-year-old Caucasian boy with severe congenital hemophilia A (endogenous FVIII level below 0.01IU/mL), the intron 22 inversion of the F8 gene and high-titer FVIII inhibitor. The gene discussed is F8; the disease is hemophilia A.